Bernstein analyst Miki Sogi maintained a Buy rating on Astellas Pharma (ALPMF – Research Report) today and set a price target of Yen2,100.00.

The company has discontinued the Phase I/II trial of its only clinical candidate due to a potential “unfavourable ...

Astellas Pharma (ALPMY) announced the Food and Drug Administration issued a Complete Response Letter regarding the supplemental new drug ...

Astellas said in a press release that the FDA comments in the CRL relate to proposed labeling language, not safety.

"Astellas stands by the clinical profile of Izervay, the only FDA-approved GA treatment that consistently demonstrated ...

Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) saw a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 9,100 shares ...

The global cellular reprogramming tools market is on an impressive growth trajectory, with a projected valuation of USD 400 ...

Japan Steel Works topped with overnight gains of 11.6 percent followed by Fujikura that added 7.2 percent. Ebara Corp rallied 5.2 percent followed by Nidec Corp and Panasonic that added more than 4 ...

PITTSBURGH--KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced the expansion of ...

The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less ...

Many companies just iterate indefinitely without ever making progress toward an actual drug,” said one biotech VC on a panel ...

Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...